Soligenix, Inc. (SNGX) provides corporate update and guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selloff resumes, Trump says US must react to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Micron to deliver 'another strong quarter', Goldman says
- Salesforce to acquire metering platform M3TER for consumption billing
Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
January 14, 2020 7:00 AM ESTPRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Dear Friends and Shareholders,
Let me start by wishing you a Healthy and Happy New Year! I wanted to take this opportunity to provide a corporate update, as well... More
